You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
|
|---|---|
| Published in |
Genome Medicine, October 2016
|
| DOI | 10.1186/s13073-016-0365-1 |
| Pubmed ID | |
| Authors |
Jake S. O’Donnell, Mark J. Smyth, Michele W. L. Teng |
| Abstract |
Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large number of patients present with or develop resistance to them. Unfortunately, very little is known regarding the mechanisms of resistance to such therapies. A recent study sought to identify mutations associated with resistance to anti-PD1 therapy. Results from this study demonstrated that mutations which affected the sensitivity of tumor cells to T-cell-derived interferons, and mutations limiting tumor-cell antigen presentation, could cause acquired resistance. These findings have significant implications for understanding the mechanisms by which anti-PD1 therapies exert their efficacy, comprehending why and how some patients acquire resistance over time, and ultimately guiding the development of combination therapies designed to overcome, or potentially prevent, the development of acquired immunotherapeutic resistance. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 17% |
| United Kingdom | 1 | 17% |
| Unknown | 4 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 67% |
| Scientists | 2 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| France | 1 | 1% |
| Unknown | 77 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 15% |
| Student > Master | 11 | 14% |
| Student > Bachelor | 10 | 13% |
| Student > Ph. D. Student | 9 | 11% |
| Other | 8 | 10% |
| Other | 10 | 13% |
| Unknown | 19 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 23 | 29% |
| Medicine and Dentistry | 16 | 20% |
| Agricultural and Biological Sciences | 12 | 15% |
| Immunology and Microbiology | 3 | 4% |
| Chemistry | 2 | 3% |
| Other | 4 | 5% |
| Unknown | 19 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2018.
All research outputs
#4,642,289
of 23,650,645 outputs
Outputs from Genome Medicine
#878
of 1,468 outputs
Outputs of similar age
#75,966
of 315,832 outputs
Outputs of similar age from Genome Medicine
#20
of 31 outputs
Altmetric has tracked 23,650,645 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,468 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.9. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,832 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.